drugset
drugset / Trial / NCT03901001

Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza

NCT03901001 ↗

Phase 3 Unknown 160 enrolled Chinese University of Hong Kong
RandomizedParallel-groupOpen-labelTreatment

Summary

Seasonal influenza epidemics are important causes of mortality and morbidity. Cytokine dysregulation, with high levels of pro-inflammatory cytokines, occurs in patients with severe influenza A(H1N1)pdm09 virus infection, A(H5N1) infection, and A(H7N9) infection. We aim to investigate the effects of adjunctive sirolimus in adults hospitalized with influenza A or B infections involving the lower respiratory tract.

Timeline

Start
2023-05-08
Primary completion
2025-10-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sirolimus Small molecule 1 mg Oral
Comparator Oseltamivir Small molecule 75 mg Oral

Indications

influenza